News

Carilion CEO Nancy Howell Agee to Retire

Nancy Howell Agee, who led Carilion through more than a decade of transformative change, will step down as CEO Sept. 30. Steve Arner, who was promoted to president in May 2023, will succeed Agee and become president and CEO Oct. 1.

The leadership transition comes after Agee’s long and distinguished career at Carilion, beginning as a nurse in 1973. She was named Carilion’s president and CEO in 2011, becoming the health system’s seventh – and only female — top executive.

Agee earned national recognition for reorganizing Carilion as a fully integrated, physician-led clinic that includes a medical school and research institute with Virginia Tech, and served as chair of the American Hospital Association’s Board of Trustees in 2018.

She will serve as CEO emeritus through September 2025 and focus on philanthropy, growing Carilion’s partnerships and continuing to develop the health system’s reputation statewide and nationally.

Steve is a strong and capable leader whose commitment to our mission and deep knowledge of our entire organization make him well-suited for the CEO role,” said James Hartley, chairman of Carilion Clinic’s board of directors.

Arner has served as chief operating officer since 2012. He spearheaded more than $500 million in facilities investments, including the Crystal Spring Tower addition to Carilion Roanoke Memorial Hospital, on track for completion in 2025, and the recently opened Carilion Children’s and Mental Health facilities at Tanglewood. During the Covid-19 pandemic, he led the health system’s response, while also serving as chair of the Virginia Hospital and Healthcare Association.

“Carilion today is a nationally ranked academic health system that provides an extraordinary range of services, from primary care to the most advanced, complex care,” said Arner. “In some respects, it’s a far different organization than the one I joined more than 25 years ago. What has remained the same since the day I started is Carilion’s laser-like focus on its mission and our community, and I look forward to continuing on the path to growth and collaboration.”

Hartley added, “Carilion and our community have been the fortunate beneficiaries of Nancy’s talents for more than 50 years. I’m grateful to her for her continued service, and I’m grateful to Steve for advancing us to our next chapter.”

Read more here.

Recent News

05/22/2026

BIO Statement on Veto of Prescription Drug Affordability Boards (PDAB) in VirginiaPatrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription Drug Affordability Board (PDAB) and imposed arbitrary price controls in Virginia. The Governor’s action recognized an important point: even well-intentioned healthcare policies must be carefully designed to avoid unintended consequences for patients, providers, employers, and Virginia’s innovation economy. “BIO is proud to represent biotechnology companies developing the next generation of life-changing medicines, including many in the Commonwealth. We believe policymakers play a critically important role in helping advance both patient access to treatments and the continued growth of the life sciences sector. “We look forward to working with the Governor’s Administration, the General Assembly, Virginia Bio and other stakeholders to advance practical, patient-centered policy solutions that improve affordability while preserving access to care and the innovation ecosystem patients depend on.”

Patrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription

05/21/2026

Virginia Bio Applauds Governor Spanberger’s Veto of SB 271 and HB 483

The Virginia Biotechnology Association (Virginia Bio) today expressed strong support for Governor Abigail Spanberger’s decision to veto Senate Bill 271 and House Bill 483, legislation that would have established a Prescription Drug Affordability Advisory Panel (PDAAP) in the Commonwealth. Virginia Bio and the Virginia Chamber of Commerce sent a joint letter to Governor Spanberger commending

05/21/2026

New Global Clinical Society to Bring Focused Ultrasound Into Mainstream Medicine

The Focused Ultrasound Foundation today announced the launch of the International Focused Ultrasound Society (IFUS), a new organization dedicated to advancing clinical practice and accelerating adoption of focused ultrasound – a revolutionary, noninvasive therapeutic technology. Established as a program of the Focused Ultrasound Foundation, IFUS aggregates and expands the Foundation’s activities related to clinical implementation